The short version of lipolysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-21. Anything still debated is marked as such rather than presented as settled.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Johnny Rep, former Ajax player, claimed that "everyone was on something". He recounted injections for everyone on 1 November 1979, ahead of a match of his team, Saint-Etienne, against PSV Eindhoven. Pierre Poty, who was physician of the club at that time, also revealed that he worked with uppers and reasoned it with the fantastic effects. Fritz Kessel, also physician, worked for the Dutch national side for 30 years and revealed that drugs were common in the 1974 and 1978 FIFA World Cups. He said that to Guido Derksen, writer of Voetbal Mysteries, who wrote that players "consumed tons of amphetamines." An investigative commission of sports medicine in Freiburg claims that in the late 1970s and in the 1980s Stuttgart and Freiburg football clubs were operating with Anabolika. VfB Stuttgart reordered Anabolika at least once. In 1987, Toni Schumacher wrote about a long-running tradition of doping in the Bundesliga, claiming that lots of players were taking Captagon. He himself experimented with it and the effects were: Increased aggression, lower pain threshold, increased focus, confidence and endurance. The by effect was sleeping problems. In Köln he was chauffeuring his colleagues to the doctor who gave them pills and injections, presumably anabolics and stimulants. In the national team he mentioned a "walking chemist" and hormone use. Despite being supported by Paul Breitner he had to leave Köln after 544 games.
Polyamides can also be synthesized from dinitriles using acid catalysis via an application of the Ritter reaction. This method is applicable for preparation of nylon 1,6 from adiponitrile, formaldehyde and water. Additionally, polyamides can be synthesized from glycols and dinitriles using this method as well.
Chemical composition distribution Chemical composition distribution (CCD) together with the molar mass distribution (MMD) and their interdependence define the microstructure of a polyolefin. CCD is often the most discriminating feature of a complex polyolefin. Some instruments in Polymer Char's range are available for this purpose:
Sources: en.wikipedia.org
=== Marriages and children === Galloway has been married four times and has six children. In 1979, he married Elaine Fyffe, with whom he has a daughter. The couple separated in 1987 and divorced in 1999. In 1994, Galloway married Amineh Abu-Zayyad, a Palestinian biologist, in a non-legally binding Islamic ceremony; a legally binding civil ceremony followed in March 2000. Abu-Zayyad was granted a divorce in February 2009, after an estrangement of several years, on the grounds of "unreasonable behaviour"; her petition was not contested. Galloway married Rima Husseini, his former researcher, in a non-legally binding Islamic ceremony in 2005. Galloway had two sons with Husseini, who is from Lebanon. On 31 March 2012 he married his fourth wife, the Dutch–Indonesian anthropologist Putri Gayatri Pertiwi, then 27, in Amsterdam. The initial event was followed by a traditional Javanese wedding ceremony in Sumatra and a civil marriage at the House of Commons in September 2012. Pertiwi worked as a consultant for a Dutch research firm and as a co-presenter of Galloway's TV show Sputnik. The couple have three children.
== History == The mdx mouse was first described in 1984 by Bulfield et al. in a colony of C57BL/10ScSn mice, showing elevated muscle creatine kinase (CK) and histological lesions characteristic of muscular dystrophy. In 1989, Sicinski et al. identified the precise mutation: a C-to-T transition (nonsense point mutation) in exon 23 of the Dmd gene, creating a premature stop codon and abolishing full-length dystrophin expression. This makes mdx mice a key model for Duchenne muscular dystrophy.
== See also == Biological half-life, the time it takes for a substance to lose half of its pharmacologic, physiologic, or radiologic activity Effective half-life, the effective radioactive half-life in organisms after accounting for excretion Half-life of knowledge, the amount of time that has to elapse before half of the knowledge or facts in a particular area is superseded or shown to be untrue Half a Life (disambiguation)
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.